Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 19, 2004. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares and American Depositary Receipts (ADRs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions related to employee benefit plans and does not contain financial performance data.
Material Changes
The filing details two specific movements in shareholdings associated with employee plans:
- US Retirement Savings Plan: On October 14, 2004, the number of Ordinary Share ADRs held by the fund decreased from 19,011,465 to 18,973,304 due to a fund movement. The average price was $42.41.
- Employee Share Option Plan: On October 15, 2004, the GlaxoSmithKline Employee Trust transferred 4,932 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Management Commentary and Risks
The filing identifies that Directors Dr. J.P. Garnier, Dr. T. Yamada, and Mr. J.D. Coombe are potentially interested in the shares held within the discretionary funds (the US Retirement Savings Plan and the GSK Trust) in the same manner as other employees. No specific risks, contingencies, or forward-looking guidance are provided in this text.
Investor Verification Points
- Verify the impact of the ADR reduction on the total outstanding share count.
- Confirm the specific allocation of the 4,932 shares transferred to the 1991 Employee Share Option Plan.
- Review the full 20-F annual report for comprehensive financial metrics absent from this 6-K filing.